Key Findings
At BIO International 2026, Thermo Fisher Scientific unveiled groundbreaking products and significant manufacturing capacity expansions, aiming to accelerate cell and gene therapy (CGT) and biologics production. The company introduced the Gibco™ CTS™ DynaXS™ single-use bioreactor, a revolutionary technology for scalable cell therapy manufacturing, while also announcing substantial increases in biologics drug substance production capacity in the US and Switzerland, alongside the expansion of its global Bioprocess Design Center (BDC) network.
Technical / Clinical Details
- Gibco™ CTS™ DynaXS™ Single-Use Bioreactor: This novel bioreactor offers high flexibility and scalability for cell therapy product manufacturing. Single-use technology reduces the risk of cross-contamination and enables rapid changeovers, thereby improving manufacturing efficiency and cost-effectiveness. It is specifically designed to support closed and automated processes, addressing the complexities of CGT manufacturing.
- Expanded Biologics Drug Substance Capacity: Thermo Fisher Scientific is significantly expanding its biologics drug substance manufacturing capacity at existing facilities in the US and Switzerland. This investment is strategically aimed at meeting the growing demand for monoclonal antibodies, recombinant proteins, and other advanced biopharmaceuticals.
- New GMP Monoclonal Antibody Manufacturing: A new GMP-compliant monoclonal antibody manufacturing facility is scheduled to open in Plainville, Massachusetts, in late 2026. This expansion further strengthens the company’s Contract Development and Manufacturing Organization (CDMO) service portfolio, enabling comprehensive support for clients.
- Global BDC Network Expansion: The expansion of the Bioprocess Design Center (BDC) network is intended to provide clients with access to expert knowledge and resources for optimizing bioprocesses from early development to commercial production. This is crucial for enabling rapid and efficient process development.
Background & Context
The biopharmaceutical industry is experiencing unprecedented growth driven by the emergence of novel modalities such as cell and gene therapies and monoclonal antibodies. However, manufacturing these advanced therapeutics is complex, requiring significant capital investment, specialized expertise, and stringent regulatory compliance. Thermo Fisher Scientific, as a CDMO, plays a vital role in providing comprehensive solutions to pharmaceutical companies facing these challenges, thereby accelerating the market entry of therapies.
Strategic Significance & Outlook
These strategic investments and new product introductions by Thermo Fisher Scientific hold significant implications for shaping the future of biopharmaceutical manufacturing. The evolution of single-use technologies and the strengthening of its global manufacturing and development network are foundational to shortening CGT and biologics development cycles, making innovative treatments accessible to more patients. Integration with AI-enabled research capabilities promises to enhance efficiency from early development stages and accelerate the discovery of next-generation therapies.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments